Clinical trials: HIV-infection/AIDS
HIV-1-infection
Efavirenz 400mg in Treatment-naïve Chinese HIV-infected Patients
Evaluating the efficacy, pharmacodynamics, and safety of Efavirenz 400mg in treatment-naïve Chinese HIV-infected patients.
- Trial name
- NCT04596488
- Testing
- Efavirenz 400mg
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Peking Union Medical College Hospital
Hepatitis b Virus
A Study to Test the Efficacy of the HBV Vaccine and to Look at the Prevalence of HBV Infection
The prevalence of Hepatitis B core antigen in the Thai population is about 70 %, no data of isolated Hepatitis B core antigen is reported.
- Trial name
- NCT00476411
- Testing
- HBV vaccine
- Where
- Thailand
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
HIV Infections
A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection
To evaluate the clinical toxicity, safety, and MTD of WF 10 ( TCDO ) intravenous solution administered to patients with HIV infection. To evaluate the potential anti-HIV activity of TCDO.
- Trial name
- NCT00002119
- Testing
- WF10
- Where
- United States
- Sponsor
- Oxo Chemie GmbH
HIV Infections
Phase I/II Study of Curdlan Sulfate
To assess the safety and tolerance of curdlan sulfate, as well as its anti-HIV activity, in HIV-infected patients with CD4 T-lymphocytes less than 500 cells/mm3, using first single doses and then, after FDA review, daily doses…
- Trial name
- NCT00002100
- Testing
- Curdlan sulfate
- Where
- United States
- Sponsor
- AJI Pharma USA
HIV Infections, Acquired Immunodeficiency Syndrome
Vicriviroc in HIV(R5/X4)-Treatment Experienced Subjects (Study P05057AM5)(COMPLETED)
Vicriviroc (vye-kri-VYE-rock) is an investigational drug (not yet approved by Government Regulatory Authorities for commercial use) that belongs to a new class of drugs, called CCR5 receptor blockers.
- Trial name
- NCT00551330
- Testing
- Vicriviroc
- Volunteers
- 111 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Getting to Zero Among HHI MSM in the American South
This study will evaluate a status-neutral integrated strategy to improve access to and uptake of HIV prevention and treatment services for the highest HIV incidence (HHI) men who have sex with men (MSM) in participating…
- Trial name
- NCT05075967
- Testing
- Health Access Coalitions, Social Media, Peer Support
- Where
- United States
- Volunteers
- 2,700 people, healthy volunteers welcome
- Sponsor
- HIV Prevention Trials Network
HIV-Associated Lipodystrophy Syndrome
Safety and Efficacy of Intradermal Injections of Newfill Versus Eutrophill in the Treatment of Facial Lipoatrophy in HIV-infected Patients ANRS 132 SMILE
Treatment of facial lipoatrophy with dermal injections polylactic acid (Newfill TM) is a safe procedure and has been now widely used with a good efficacy.
- Trial name
- NCT00383734
- Testing
- Newfill, Eutrophill
- Where
- France
- Volunteers
- 148 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV Infections
A Study of Dextran Sulfate in HIV-Infected Patients and in Patients With AIDS or AIDS Related Complex (ARC)
To determine the effectiveness and safety of dextran sulfate (DS) as a treatment for patients with AIDS, AIDS related complex (ARC), or asymptomatic HIV infection with or without persistent generalized lymphadenopathy (PGL), and…
- Trial name
- NCT00001009
- Testing
- Dextran sulfate
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Immunodeficiency Virus
The Tolerability of, and Adherence to, Dolutegravir With Co-formulated Tenofovir-emtricitabine for HIV Non-occupational Post-exposure Prophylaxis
This study aims to describe the proportion of participants with non-occupational post-exposure prophylaxis (NPEP) failure, defined as NPEP non-completion (including loss to follow-up) at week 4 or primary HIV infection at week 4…
- Trial name
- dPEP (NCT02211690)
- Testing
- dolutegravir 50 mg (one tablet daily), emtricitabine-tenofovir 300/200 mg (one tablet daily)
- Where
- 5 sites in Australia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Andrew Carr
HIV Infections
Safety and Immune Response Assessment Study of Killed-whole HIV-1 Vaccine (SAV001-H) in Chronic HIV-1 Infected Patients
The purpose of this study is to examine the safety, tolerability, and immune response to killed-whole HIV-1 (SAV001-H) vaccine as a primary vaccination regimen in HIV infected individuals.
- Trial name
- NCT01546818
- Testing
- SAV001-H
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Sumagen
HIV/AIDS
Translation of Basic Research in Cognitive Science to HIV Risk
A randomized trial was conducted at drug diversion educational programs with a sample of 343 adult drug offenders who volunteered for the study.
- Trial name
- NCT03175250
- Testing
- Health Education, Action Plan, Memory Practice
- Volunteers
- 343 people, healthy volunteers welcome
- Sponsor
- Claremont Graduate University
Human Immunodeficiency Virus
Package of Resources for Assisted Contact Tracing: Implementation, Costs, and Effectiveness
Having health workers assist HIV-infected persons with the recruitment and testing of their sexual contacts and biological children is an effective and efficient way of identifying additional HIV-infected persons in need of HIV…
- Trial name
- PRACTICE (NCT05343390)
- Testing
- Enhanced implementation package, Standard implementation package
- Where
- 33 sites in Malawi
- Volunteers
- 841 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
HIV/AIDS, Housing Problems
Enhanced Housing Placement Assistance
Randomized controlled trial of housing placement assistance for homeless persons with HIV
- Trial name
- EHPA (NCT03334825)
- Testing
- Enhanced housing placement assistance, Standard housing placement assistance
- Volunteers
- 236 people, healthy volunteers welcome
- Sponsor
- New York City Department of Health and Mental Hygiene
Healthy
A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy Participants
The purpose of this study is to evaluate the single-dose pharmacokinetics and pivotal bioequivalence of Darunavir (DRV) 800 milligram (mg), Emtricitabine (FTC) 200 mg, and tenofovir alafenamide (TAF) 10 mg when administered as a…
- Trial name
- NCT02578550
- Testing
- Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide fixed-dose combination (FDC), Emtricitabine/tenofovir alafenamide FDC, Darunavir
- Where
- Netherlands
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Janssen Sciences Ireland UC
HIV Infections
Taste Properties of HIV Inhibitor
The purpose of the study is to assess the taste properties of HIV inhibitor
- Trial name
- NCT02608918
- Testing
- BMS-955176
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV/AIDS
M-Suubi: A Multi-Level Integrated Intervention to Reduce the Impact of HIV Stigma
M-Suubi, a three arm cluster randomized study will examine the effects and cost-effectiveness of a multi-level intervention on HIV viral suppression among 840 adolescents living with HIV (ALHIV) enrolled in 42 secondary schools…
- Trial name
- NCT05307250
- Testing
- Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE, Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE plus Group-based stigma reduction for educators (GED-HIVSR)., Bolstered Standard of Care (BSOC)
- Where
- Uganda
- Volunteers
- 1,851 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
HIV
Phase II Randomised Controlled Trial of Memory Work Therapy at PASADA, Tanzania
Memory Work Therapy (MWT) has been developed to improve psycho-social outcomes for children living with HIV who are orphaned. This phase 2 trial aims to determine whether attending the intervention improves outcomes compared to…
- Trial name
- MWT (NCT02180750)
- Testing
- Memory Work Therapy, Standard care
- Where
- Tanzania
- Volunteers
- 48 people
- Sponsor
- Pastoral Activities and Service for AIDS Dar-Es-Salaam Archdiocese
HIV Infections
Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of an HIV vaccine (gp145 C.6980) with aluminum hydroxide adjuvant in healthy, HIV-1-uninfected adults in the United States.
- Trial name
- NCT03382418
- Testing
- gp145 C.6980 Vaccine, Aluminum Hydroxide Adjuvant
- Where
- 3 sites in United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HPV - Anogenital Human Papilloma Virus Infection, HSIL, High Grade Squamous Intraepithelial Lesions
E6/E7 mRNA Performance to Detect HSIL and Cost-effectiveness Analysis of This Screening Strategy in HIV + MSM
This study evaluates the positive and negative predictive value of E6/E7 mRNA expression for anal HSIL and its capacity to predict incident HSIL in HIV + MSM. We also analyse the cost-effectiveness of this new screening strategy.
- Conditions
- HPV - Anogenital Human Papilloma Virus Infection, HSIL, High Grade Squamous Intraepithelial Lesions, Anal Cancer, Hiv
- Trial name
- ELAVI-67 (NCT03357991)
- Where
- Spain
- Volunteers
- 355 people
- Sponsor
- Hospital Universitari de Bellvitge
HIV Disease
Therapy to Elevate CD4 Counts in HIV-1 Disease
For more than 20 years, alpha-1-proteinase inhibitor therapy has been the standard treatment for patients who have inherited alpha-1-proteinase inhibitor deficiency.
- Trial name
- NCT01370018
- Testing
- alpha-1-Proteinase Inhibitor
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Institute for Human Genetics and Biochemistry
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.